Therapeutic potential of stem cells for preterm infant brain damage: can we move from the heterogeneity of preclinical and clinical studies to established therapeutics?
Sofia Passera, Marta Boccazzi, Cindy Bokobza, Valerie Faivre, Fabio Mosca, Juliette Van Steenwinckel, Monica Fumagalli, Pierre Gressens and Bobbi Fleiss
Biochemical Pharmacology 2021, 114461; https://doi.org/10.3390/biom11010099
Received: 10 December 2020 / Revised: 27 January 2021 / Accepted: 2 February 2021 / Available online: 8 February 2021
Microglia-Mediated Neurodegeneration in Perinatal Brain Injuries
Bobbi Fleiss, Juliette Van Steenwinckel, Cindy Bokobza, Isabelle K. Shearer, Emily Ross-Munro and Pierre Gressens
Biomolecules 2021, 11(1), 99; https://doi.org/10.3390/biom11010099
Received: 29 November 2020 / Revised: 8 January 2021 / Accepted: 11 January 2021 / Published: 13 January 2021
This review looks at strategies developed experimentally to modulate microglia and reduce brain injury in babies. It focusses on four causes of perinatal brain injury which occur frequently in both westernised and emerging countries, including EoP and neonatal stroke, and reviews pharmacological approaches as well as novel nanoparticle mediated therapies.
Preterm Brain Injury, Antenatal Triggers, and Therapeutics: Timing Is Key
Daan R.M.G. Ophelders, Ruth Gussenhoven, Luise Klein, Reint K. Jellema, Rob J.J. Westerlaken, Matthias C. Hütten, Jeroen Vermeulen, Guido Wassink, Alistair J. Gunn and Tim G.A.M. Wolfs